ArriVent BioPharma Inc. Common Stock (AVBP) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    ArriVent BioPharma Inc. C...

    NASDAQ: AVBP · Real-Time Price · USD
    19.84
    1.01 (5.36%)
    At close: Oct 03, 2025, 3:59 PM
    19.84
    0.00%
    After-hours: Oct 03, 2025, 04:04 PM EDT

    ArriVent BioPharma Common Stock Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a n/a n/a n/a
    Gross Profit
    		 n/a n/a n/a n/a
    Operating Income
    		 -94.31M -74.59M -36.91M -8.7M
    Interest Income
    		 13.82M 5.26M n/a n/a
    Pretax Income
    		 -80.49M -69.33M -36.91M -51.61M
    Net Income
    		 -80.49M -69.33M -36.91M -51.61M
    Selling & General & Admin
    		 15.3M 9.71M 6.47M 2.26M
    Research & Development
    		 79M 64.88M 30.43M 6.43M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 94.31M 74.59M 36.91M 8.7M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a -754K
    Cost & Expenses
    		 -94.31M 74.59M 36.91M 8.7M
    Income Tax Expense
    		 n/a n/a n/a -11.59M
    Shares Outstanding (Basic)
    		 31.47M 31.96M 33.49M 1.28M
    Shares Outstanding (Diluted)
    		 31.47M 31.96M 33.49M 1.28M
    EPS (Basic)
    		 -2.56 -2.17 -1.1 -40.44
    EPS (Diluted)
    		 -2.56 -2.17 -1.1 -40.44
    EBITDA
    		 -80.49M -74.59M -36.91M -51.61M
    EBIT
    		 -80.49M -74.59M -36.91M -11.59M
    Depreciation & Amortization
    		 n/a n/a 36.91M 11.59M

    Add to Watchlist